Stoke Therapeutics (STOK) Stock Forecast, Price Target & Predictions

STOK Stock Forecast

Stoke Therapeutics stock forecast is as follows: an average price target of $30.60 (represents a 170.56% upside from STOK’s last price of $11.31) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

STOK Price Target

The average price target for Stoke Therapeutics (STOK) is $30.60 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $58.00 to $18.00. This represents a potential 170.56% upside from STOK's last price of $11.31.

STOK Analyst Ratings

Buy

According to 6 Wall Street analysts, Stoke Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for STOK stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Stoke Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 11, 2024	Marc Goodman	Leerink Partners	$18.00	$11.84	52.03%	59.15%
Sep 11, 2024	Debjit Chattopadhyay	H.C. Wainwright	$35.00	$15.32	128.46%	209.46%
May 07, 2024	Sumant Kulkami	Canaccord Genuity	$20.00	$11.87	68.49%	76.83%
Mar 26, 2024	Joseph Stringer	Needham	$22.00	$6.50	238.46%	94.52%
Mar 26, 2024	Sumant Kulkami	Canaccord Genuity	$21.00	$10.92	92.31%	85.68%
Nov 14, 2022	-	Needham	$25.00	$9.33	167.95%	121.04%
Apr 26, 2021	Judah Frommer	Credit Suisse	$58.00	$32.50	78.46%	412.82%

Row per page

Go to

The latest Stoke Therapeutics stock forecast, released on Oct 11, 2024 by Marc Goodman from Leerink Partners, set a price target of $18.00, which represents a 52.03% increase from the stock price at the time of the forecast ($11.84), and a 59.15% increase from STOK last price ($11.31).

Stoke Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	5
Avg Price Target	-	$26.50	$23.20
Last Closing Price	$11.31	$11.31	$11.31
Upside/Downside	-100.00%	134.31%	105.13%

In the current month, the average price target of Stoke Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Stoke Therapeutics's last price of $11.31. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 11, 2024	Cowen & Co.	Buy	Buy	Hold
Sep 11, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 28, 2024	Needham	Buy	Buy	Hold
Jun 28, 2024	Canaccord Genuity	Underperform	Underperform	Hold
May 07, 2024	Canaccord Genuity	Buy	Buy	Hold
May 06, 2024	Wedbush	Buy	Buy	Hold
May 06, 2024	Needham	Underperform	Underperform	Hold
Apr 04, 2024	Needham	Underperform	Underperform	Hold
Apr 04, 2024	Wedbush	Buy	Buy	Hold
Mar 26, 2024	Needham	Buy	Buy	Hold

Row per page

Go to

Stoke Therapeutics's last stock rating was published by Cowen & Co. on Sep 11, 2024. The company gave STOK a "Buy" rating, the same as its previous rate.

Stoke Therapeutics Financial Forecast

Stoke Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22
Revenue	-	-	-	-	-	-	-	-	-	$3.31M	$-2.48M	$5.15M	$3.27M	$2.90M	$3.23M	$3.00M
Avg Forecast	$12.27M	$2.27M	$2.27M	$2.27M	$4.10M	$3.83M	$3.70M	$3.26M	$3.66M	$3.64M	$3.44M	$3.00M	$2.86M	$2.72M	$2.64M	$50.00M
High Forecast	$13.31M	$2.46M	$2.46M	$2.46M	$4.23M	$3.86M	$3.70M	$3.26M	$4.95M	$3.64M	$3.74M	$3.26M	$3.11M	$2.72M	$2.64M	$50.00M
Low Forecast	$11.26M	$2.08M	$2.08M	$2.08M	$3.70M	$3.80M	$3.70M	$3.26M	$2.48M	$3.64M	$3.16M	$2.75M	$2.63M	$2.72M	$2.64M	$50.00M
# Analysts	1	1	1	2	6	3	3	3	6	3	3	3	4	4	4	4
Surprise %	-	-	-	-	-	-	-	-	-	0.91%	-0.72%	1.72%	1.14%	1.07%	1.22%	0.06%

Stoke Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $3.66M, with a low forecast of $2.48M, and a high forecast of $4.95M. STOK's average Quarter revenue forecast represents a 10.75% increase compared to the company's last Quarter revenue of $3.31M (Sep 23).

Stoke Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22
# Analysts	1	1	1	2	6	3	3	3	6	3	3	3	4	4	4	4
EBITDA	-	-	-	-	-	-	-	-	-	$-27.23M	$-33.26M	$-24.69M	$-27.18M	$-26.76M	$-25.24M	$-24.55M
Avg Forecast	$2.45M	$453.33K	$453.33K	$453.33K	$820.00K	$765.71K	$740.54K	$652.05K	$732.70K	$728.57K	$688.89K	$600.00K	$572.53K	$544.44K	$528.12K	$-60.23M
High Forecast	$2.66M	$491.93K	$491.93K	$491.93K	$845.36K	$772.07K	$740.57K	$652.07K	$990.13K	$728.59K	$747.54K	$651.08K	$621.28K	$544.44K	$528.12K	$-48.18M
Low Forecast	$2.25M	$416.25K	$416.25K	$416.25K	$739.69K	$759.36K	$740.51K	$652.02K	$495.07K	$728.56K	$632.53K	$550.92K	$525.70K	$544.44K	$528.12K	$-72.27M
Surprise %	-	-	-	-	-	-	-	-	-	-37.38%	-48.28%	-41.15%	-47.46%	-49.15%	-47.79%	0.41%

undefined analysts predict STOK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Stoke Therapeutics's previous annual EBITDA (undefined) of $NaN.

Stoke Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22
# Analysts	1	1	1	2	6	3	3	3	6	3	3	3	4	4	4	4
Net Income	-	-	-	-	-	-	-	-	-	$-24.54M	$-30.65M	$-18.30M	$-22.05M	$-24.08M	$-23.22M	$-24.40M
Avg Forecast	$-28.45M	$-36.20M	$-34.09M	$-33.38M	$-28.39M	$-29.30M	$-30.88M	$-34.36M	$-34.29M	$-35.64M	$-35.76M	$-39.49M	$-40.17M	$-38.16M	$-38.34M	$-61.10M
High Forecast	$-25.43M	$-32.35M	$-30.46M	$-31.00M	$-27.08M	$-26.18M	$-27.59M	$-30.71M	$-26.55M	$-31.85M	$-31.96M	$-35.29M	$-35.90M	$-38.16M	$-38.34M	$-48.88M
Low Forecast	$-31.60M	$-40.21M	$-37.86M	$-35.17M	$-29.71M	$-32.54M	$-34.30M	$-38.17M	$-39.26M	$-39.58M	$-39.72M	$-43.86M	$-44.62M	$-38.16M	$-38.34M	$-73.32M
Surprise %	-	-	-	-	-	-	-	-	-	0.69%	0.86%	0.46%	0.55%	0.63%	0.61%	0.40%

Stoke Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. STOK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Stoke Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22
# Analysts	1	1	1	2	6	3	3	3	6	3	3	3	4	4	4	4
SG&A	-	-	-	-	-	-	-	-	-	$10.27M	$10.23M	$10.21M	$9.38M	$9.94M	$10.11M	$9.49M
Avg Forecast	$26.60M	$4.92M	$4.92M	$4.92M	$8.89M	$8.30M	$8.03M	$7.07M	$7.95M	$7.90M	$7.47M	$6.51M	$6.21M	$5.76M	$5.59M	$23.51M
High Forecast	$28.87M	$5.33M	$5.33M	$5.33M	$9.17M	$8.37M	$8.03M	$7.07M	$10.74M	$7.90M	$8.11M	$7.06M	$6.74M	$5.76M	$5.59M	$28.22M
Low Forecast	$24.43M	$4.51M	$4.51M	$4.51M	$8.02M	$8.23M	$8.03M	$7.07M	$5.37M	$7.90M	$6.86M	$5.97M	$5.70M	$5.76M	$5.59M	$18.81M
Surprise %	-	-	-	-	-	-	-	-	-	1.30%	1.37%	1.57%	1.51%	1.73%	1.81%	0.40%

Stoke Therapeutics's average Quarter SG&A projection for Dec 23 is $7.95M, based on 6 Wall Street analysts, with a range of $5.37M to $10.74M. The forecast indicates a -22.64% fall compared to STOK last annual SG&A of $10.27M (Sep 23).

Stoke Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22
# Analysts	1	1	1	2	6	3	3	3	6	3	3	3	4	4	4	4
EPS	-	-	-	-	-	-	-	-	-	$-0.55	$-0.00	$-0.43	$-0.56	$-0.61	$-0.59	$-0.65
Avg Forecast	$-0.51	$-0.64	$-0.60	$-0.59	$-0.50	$-0.52	$-0.55	$-0.61	$-0.61	$-0.63	$-0.63	$-0.70	$-0.71	$-0.68	$-0.69	$0.36
High Forecast	$-0.45	$-0.57	$-0.54	$-0.55	$-0.48	$-0.46	$-0.49	$-0.55	$-0.47	$-0.57	$-0.57	$-0.63	$-0.64	$-0.68	$-0.69	$0.36
Low Forecast	$-0.56	$-0.71	$-0.67	$-0.62	$-0.53	$-0.58	$-0.61	$-0.68	$-0.70	$-0.70	$-0.70	$-0.78	$-0.79	$-0.68	$-0.69	$0.36
Surprise %	-	-	-	-	-	-	-	-	-	0.87%	0.00%	0.61%	0.79%	0.89%	0.86%	-1.80%

According to undefined Wall Street analysts, Stoke Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to STOK previous annual EPS of $NaN (undefined).

Stoke Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
BCEL	Atreca	$0.09	$4.00	4344.44%	Buy
PASG	Passage Bio	$0.51	$6.00	1076.47%	Buy
BDTX	Black Diamond Therapeutics	$2.43	$14.75	507.00%	Buy
ADAP	Adaptimmune Therapeutics	$0.66	$2.83	328.79%	Buy
RLAY	Relay Therapeutics	$4.66	$19.40	316.31%	Buy
ARVN	Arvinas	$22.69	$71.00	212.91%	Buy
PLRX	Pliant Therapeutics	$12.73	$39.71	211.94%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
STOK	Stoke Therapeutics	$11.31	$30.60	170.56%	Buy

STOK Forecast FAQ

Is Stoke Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Stoke Therapeutics (STOK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of STOK's total ratings.

What is STOK's price target?

Stoke Therapeutics (STOK) average price target is $30.6 with a range of $18 to $58, implying a 170.56% from its last price of $11.31. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Stoke Therapeutics stock go up soon?

According to Wall Street analysts' prediction for STOK stock, the company can go up by 170.56% (from the last price of $11.31 to the average price target of $30.6), up by 412.82% based on the highest stock price target, and up by 59.15% based on the lowest stock price target.

Can Stoke Therapeutics stock reach $20?

STOK's average twelve months analyst stock price target of $30.6 supports the claim that Stoke Therapeutics can reach $20 in the near future.

What are Stoke Therapeutics's analysts' financial forecasts?

Stoke Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $14.89M (high $15.05M, low $14.46M), average EBITDA is $2.98M (high $3.01M, low $2.89M), average net income is $-123M (high $-112M, low $-135M), average SG&A $32.3M (high $32.64M, low $31.36M), and average EPS is $-2.182 (high $-1.98, low $-2.391). STOK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $19.07M (high $20.69M, low $17.51M), average EBITDA is $3.81M (high $4.14M, low $3.5M), average net income is $-132M (high $-119M, low $-145M), average SG&A $41.35M (high $44.87M, low $37.97M), and average EPS is $-2.345 (high $-2.116, low $-2.571).

Did the STOK's actual financial results beat the analysts' financial forecasts?

Based on Stoke Therapeutics's last annual report (Dec 2023), the company's revenue was $8.78M, which missed the average analysts forecast of $13.75M by -36.15%. Apple's EBITDA was $-115M, missing the average prediction of $2.75M by -4273.33%. The company's net income was $-105M, missing the average estimation of $-145M by -27.88%. Apple's SG&A was $41.32M, beating the average forecast of $29.82M by 38.56%. Lastly, the company's EPS was $-0.0024, missing the average prediction of $-2.577 by -99.91%. In terms of the last quarterly report (Sep 2023), Stoke Therapeutics's revenue was $3.31M, missing the average analysts' forecast of $3.64M by -9.19%. The company's EBITDA was $-27.234M, missing the average prediction of $728.57K by -3838.00%. Stoke Therapeutics's net income was $-24.542M, missing the average estimation of $-35.636M by -31.13%. The company's SG&A was $10.27M, beating the average forecast of $7.9M by 30.00%. Lastly, the company's EPS was $-0.55, missing the average prediction of $-0.632 by -13.04%